Common Contracts

34 similar Underwriting Agreement contracts by Casella Waste Systems Inc, Volitionrx LTD, Avenue Therapeutics, Inc., others

4,500,000 Shares1 CASELLA WASTE SYSTEMS, INC. Class A Common Stock UNDERWRITING AGREEMENT
Underwriting Agreement • September 18th, 2024 • Casella Waste Systems Inc • Refuse systems • New York

Casella Waste Systems, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of 4,500,000 shares of its Class A Common Stock, par value $0.01 per share (the “Class A Common Stock”). The aggregate of 4,500,000 shares to be purchased from the Company are called the “Firm Shares.” In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional 675,000 shares of Class A Common Stock (the “Additional Shares”). The Firm Shares and the Additional Shares are collectively referred to in this Agreement as the “Shares.” Raymond James & Associates, Inc., J.P. Morgan Securities LLC and Stifel, Nicolaus & Company, Incorporated are acting as the representatives of the several Underwriters and in such capacity are referred to in this Agreement as the “Representatives.”

AutoNDA by SimpleDocs
5,263,158 Shares1 CASELLA WASTE SYSTEMS, INC. Class A Common Stock UNDERWRITING AGREEMENT
Underwriting Agreement • June 15th, 2023 • Casella Waste Systems Inc • Refuse systems • New York

Casella Waste Systems, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of 5,263,158 shares of its Class A Common Stock, par value $0.01 per share (the “Class A Common Stock”). The aggregate of 5,263,158 shares to be purchased from the Company are called the “Firm Shares.” In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional 789,473 shares of Class A Common Stock (the “Additional Shares”). The Firm Shares and the Additional Shares are collectively referred to in this Agreement as the “Shares.” Raymond James & Associates, Inc. and Stifel, Nicolaus & Company, Incorporated are acting as the representatives of the several Underwriters and in such capacity are referred to in this Agreement as the “Representatives.”

4,750,000 Units* AMERICA FIRST MULTIFAMILY INVESTORS, L.P. Beneficial Unit Certificates Representing Assigned Limited Partnership Interests UNDERWRITING AGREEMENT
Underwriting Agreement • September 28th, 2021 • America First Multifamily Investors, L.P. • Finance services • New York

America First Multifamily Investors, L.P., a Delaware limited partnership (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of 5,462,500 Beneficial Unit Certificates representing Assigned Limited Partnership Interests in the Company (the “BUCs”). The aggregate of 4,750,000 BUCs to be purchased from the Company are called the “Firm Units.” In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional 712,500 BUCs (the “Additional Units”) to cover over-allotments by the Underwriters, if any. The Firm Units and the Additional Units are collectively referred to in this Agreement as the “Units.” Raymond James & Associates, Inc. is acting as the representative of the several Underwriters and in such capacity is referred to in this Agreement as the “Representative.”

2,500,000 Shares* BYRNA TECHNOLOGIES INC. Common Stock UNDERWRITING AGREEMENT
Underwriting Agreement • July 22nd, 2021 • Byrna Technologies Inc. • Miscellaneous electrical machinery, equipment & supplies • New York

Byrna Technologies Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell an aggregate of 2,500,000 shares (the “Firm Shares”) of its common stock, par value $0.001 per share (the “Common Stock”), to the several Underwriters named in Schedule I (the “Underwriters”) to this agreement (the “Agreement”), for whom Raymond James & Associates, Inc. (“Raymond James”) is acting as the representative (the “Representative”). In addition, the Company has agreed to sell to the Underwriters an option (the “Option”) to purchase up to an additional 375,000 shares of Common Stock (the “Additional Shares”) on the terms and condition stated herein. The Firm Shares and the Additional Shares are collectively referred to in this Agreement as the “Shares.”

2,250,000 Shares* BYRNA TECHNOLOGIES INC. Common Stock UNDERWRITING AGREEMENT
Underwriting Agreement • July 12th, 2021 • Byrna Technologies Inc. • Miscellaneous electrical machinery, equipment & supplies • New York

Byrna Technologies Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell an aggregate of 2,250,000 shares (the “Firm Shares”) of its common stock, par value $0.001 per share (the “Common Stock”), to the several Underwriters named in Schedule I (the “Underwriters”) to this agreement (the “Agreement”), for whom Raymond James & Associates, Inc. (“Raymond James”) is acting as the representative (the “Representative”). In addition, the Company has agreed to sell to the Underwriters an option (the “Option”) to purchase up to an additional 337,500 shares of Common Stock (the “Additional Shares”) on the terms and condition stated herein. The Firm Shares and the Additional Shares are collectively referred to in this Agreement as the “Shares.”

2,350,000 Shares* CASELLA WASTE SYSTEMS, INC. Class A Common Stock UNDERWRITING AGREEMENT
Underwriting Agreement • October 23rd, 2020 • Casella Waste Systems Inc • Refuse systems • New York

Casella Waste Systems, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of 2,350,000 shares of its Class A Common Stock, par value $0.01 per share (the “Class A Common Stock”). The aggregate of 2,350,000 shares to be purchased from the Company are called the “Firm Shares.” In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional 352,500 shares of Class A Common Stock (the “Additional Shares”). The Firm Shares and the Additional Shares are collectively referred to in this Agreement as the “Shares.” Raymond James & Associates, Inc. and BofA Securities, Inc. are acting as the representatives of the several Underwriters and in such capacity are referred to in this Agreement as the “Representatives.”

4,615,384 Shares1 CATALYST BIOSCIENCES, INC. Common Stock UNDERWRITING AGREEMENT
Underwriting Agreement • June 19th, 2020 • Catalyst Biosciences, Inc. • Pharmaceutical preparations • New York

Catalyst Biosciences, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of 4,615,384 shares of its Common Stock, par value $0.001 per share (the “Common Stock”). The aggregate of 4,615,384 shares to be purchased from the Company are called the “Firm Shares.” In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional 692,307 shares of Common Stock (the “Additional Shares”) to cover over-allotments by the Underwriters, if any. The Firm Shares and the Additional Shares are collectively referred to in this Agreement as the “Shares.” Raymond James & Associates, Inc. is acting as the representative of the several Underwriters and in such capacity is referred to in this Agreement as the “Representative.”

4,365,000 Shares* VOLITIONRX LIMITED Common Stock UNDERWRITING AGREEMENT
Underwriting Agreement • May 22nd, 2020 • Volitionrx LTD • In vitro & in vivo diagnostic substances • New York

VolitionRx Limited, a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of 4,365,000 shares of its Common Stock, par value $0.001 per share (the “Common Stock”). The aggregate of 4,365,000 shares to be purchased from the Company are called the “Firm Shares.” In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional 654,750 shares of Common Stock (the “Additional Shares”) to cover over-allotments by the Underwriters, if any. The Firm Shares and the Additional Shares are collectively referred to in this Agreement as the “Shares.” National Securities Corporation is acting as the representative of the several Underwriters and in such capacity is referred to in this Agreement as the “Representative.”

4,615,385 Shares1 CATALYST BIOSCIENCES, INC. Common Stock UNDERWRITING AGREEMENT
Underwriting Agreement • February 14th, 2020 • Catalyst Biosciences, Inc. • Pharmaceutical preparations • New York

Catalyst Biosciences, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of 4,615,385 shares of its Common Stock, par value $0.001 per share (the “Common Stock”). The aggregate of 4,615,385 shares to be purchased from the Company are called the “Firm Shares.” In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional 692,307 shares of Common Stock (the “Additional Shares”) to cover over-allotments by the Underwriters, if any. The Firm Shares and the Additional Shares are collectively referred to in this Agreement as the “Shares.” Raymond James & Associates, Inc. is acting as the representative of the several Underwriters and in such capacity is referred to in this Agreement as the “Representative.”

3,500,000 Shares* VOLITIONRX LIMITED Common Stock UNDERWRITING AGREEMENT
Underwriting Agreement • March 12th, 2018 • Volitionrx LTD • In vitro & in vivo diagnostic substances • New York

VolitionRx Limited, a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of 3,500,000 shares of its Common Stock, par value $0.001 per share (the “Common Stock”). The aggregate of 3,500,000 shares to be purchased from the Company are called the “Firm Shares.” In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional 525,000 shares of Common Stock (the “Additional Shares”) to cover over-allotments by the Underwriters, if any. The Firm Shares and the Additional Shares are collectively referred to in this Agreement as the “Shares.” Oppenheimer & Co. Inc. is acting as the representative of the several Underwriters and in such capacity is referred to in this Agreement as the “Representative.”

●] Shares* ADVANTAGE INSURANCE INC. Common Stock UNDERWRITING AGREEMENT
Underwriting Agreement • December 1st, 2017 • Advantage Insurance Inc. • Life insurance • New York

Advantage Insurance Inc., a corporation incorporated under the laws of Puerto Rico (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of [•] shares of its common stock, par value $0.01 per share (the “Common Stock”). The aggregate of [•] shares to be purchased from the Company are called the “Firm Shares.” In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional [•] shares of Common Stock (the “Additional Shares”) to cover over-allotments by the Underwriters, if any. The Firm Shares and the Additional Shares are collectively referred to in this Agreement as the “Shares.” Raymond James & Associates, Inc. (“Raymond James”) is acting as the representative of the several Underwriters and in such capacity is referred to in this Agreement as the “Representative.”

510,638 Shares FS BANCORP, INC. Common Stock UNDERWRITING AGREEMENT
Underwriting Agreement • September 11th, 2017 • FS Bancorp, Inc. • Savings institutions, not federally chartered • New York

FS Bancorp, Inc., a Washington corporation (the "Company"), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the "Underwriters"), an aggregate of 510,638 shares of its Common Stock, $0.01 par value per share (the "Common Stock"). The aggregate of 510,638 shares to be purchased from the Company are called the "Firm Shares." In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional 76,596 shares of Common Stock (the "Additional Shares") to cover over-allotments by the Underwriters, if any. The Firm Shares and the Additional Shares are collectively referred to in this agreement (this "Agreement") as the "Shares." Raymond James & Associates, Inc. is acting as the representative of the several Underwriters and in such capacity is referred to in this Agreement as "you" or the "Representative."

2,000,000 Shares of Class A Common Stock MALIBU BOATS, INC. UNDERWRITING AGREEMENT
Underwriting Agreement • August 14th, 2017 • Malibu Boats, Inc. • Ship & boat building & repairing • New York

Malibu Boats, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 2,000,000 shares of the Company’s Class A Common Stock, par value $0.01 per share (the “Common Stock”).

Shares* Avenue Therapeutics, Inc. Common Stock FORM OF UNDERWRITING AGREEMENT
Underwriting Agreement • June 23rd, 2017 • Avenue Therapeutics, Inc. • Pharmaceutical preparations • New York

Avenue Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of [__________] shares of its Common Stock, par value $0.0001 per share (the “Common Stock”). The aggregate of [_______] shares to be purchased from the Company are called the “Firm Shares.” In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional [________] shares of Common Stock (the “Additional Shares”) to cover over-allotments by the Underwriters, if any. The Firm Shares and the Additional Shares are collectively referred to in this Agreement as the “Shares.” Oppenheimer & Co. Inc. is acting as the representative of the several Underwriters and in such capacity is referred to in this Agreement as the “Representative.”

Shares* Avenue Therapeutics, Inc. Common Stock UNDERWRITING AGREEMENT
Underwriting Agreement • May 22nd, 2017 • Avenue Therapeutics, Inc. • Pharmaceutical preparations • New York

Avenue Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of [__________] shares of its Common Stock, par value $0.0001 per share (the “Common Stock”). The aggregate of [_______] shares to be purchased from the Company are called the “Firm Shares.” In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional [________] shares of Common Stock (the “Additional Shares”) to cover over-allotments by the Underwriters, if any. The Firm Shares and the Additional Shares are collectively referred to in this Agreement as the “Shares.” Raymond James & Associates, Inc. is acting as the representative of the several Underwriters and in such capacity is referred to in this Agreement as the “Representative.”

2,380,953 Shares* Bank of Commerce Holdings Common Stock UNDERWRITING AGREEMENT
Underwriting Agreement • May 10th, 2017 • Bank of Commerce Holdings • State commercial banks • California

Bank of Commerce Holdings, a California corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of 2,380,953 shares of its Common Stock, no par value per share (the “Common Stock”). The aggregate of 2,380,953 shares to be purchased from the Company are called the “Firm Shares.” In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional 357,143 shares of Common Stock (the “Additional Shares”) to cover over-allotments by the Underwriters, if any. The Firm Shares and the Additional Shares are collectively referred to in this Agreement as the “Shares.” Raymond James & Associates, Inc. is acting as the representative of the several Underwriters and in such capacity is referred to in this Agreement as the “Representative.”

1,571,429 Shares* CAROLINA FINANCIAL CORPORATION Common Stock UNDERWRITING AGREEMENT
Underwriting Agreement • January 25th, 2017 • Carolina Financial Corp • State commercial banks • Florida

Carolina Financial Corporation, a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of 1,571,429 shares of its Common Stock, par value $0.01 per share (the “Common Stock”). The aggregate of 1,571,429 shares to be purchased from the Company are called the “Firm Shares.” In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional 235,714 shares of Common Stock (the “Additional Shares”) to cover over-allotments by the Underwriters, if any. The Firm Shares and the Additional Shares are collectively referred to in this Agreement as the “Shares.” Raymond James & Associates, Inc. is acting as the representative of the several Underwriters and in such capacity is referred to in this Agreement as the “Representative.”

1,770,084 Shares SmartFinancial, Inc. Common Stock UNDERWRITING AGREEMENT
Underwriting Agreement • January 25th, 2017 • Smartfinancial Inc. • National commercial banks • New York

SmartFinancial, Inc., a Tennessee corporation (the “Company”), proposes, subject to the terms and conditions set forth in this agreement (this “Agreement”), to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), and certain stockholders of the Company named in Schedule II hereto (collectively, the “Selling Shareholders,” and each a “Selling Shareholder”) severally and not jointly propose, subject to the terms and conditions stated herein, to sell to the Underwriters, an aggregate of 1,770,084 shares of the Company’s common stock, par value $1.00 per share (the “Common Stock), of which (a) 1,600,000 shares are to be issued and sold by the Company, and (b) 170,084 shares are to be sold by the Selling Shareholders, each Selling Shareholder selling the number of shares set forth opposite such Selling Shareholder’s name in Schedule II hereto. The aggregate of 1,770,084 shares to be purchased from the Company and the Selling Shareholders are called the

Shares PARAGON COMMERCIAL CORPORATION Common Stock UNDERWRITING AGREEMENT
Underwriting Agreement • June 10th, 2016 • Paragon Commercial CORP • State commercial banks • Florida
5,147,059 Shares* ASTERIAS BIOTHERAPEUTICS, INC. Series A Common Stock and Warrants to Purchase up to 2,573,530 Shares of Series A Common Stock* UNDERWRITING AGREEMENT
Underwriting Agreement • May 10th, 2016 • Asterias Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • New York

Asterias Biotherapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of (i) 5,147,059 shares (the “Firm Shares”) of its Series A Common Stock, par value $0.0001 per share (the “Common Stock”) and (ii) warrants to purchase 2,573,530 shares of Common Stock on the terms and conditions set forth in the Warrant Agreement (as defined herein) (the “Firm Warrants,” and together with the Firm Shares, the “Firm Securities”). All of the Firm Securities are to be issued and sold by the Company. The respective amounts of the Firm Securities to be purchased by each of the several Underwriters are set forth opposite their names on Schedule I hereto. In addition, the Company has agreed to sell to the Underwriters or Raymond James & Associates, Inc. (“Raymond James”), as the case may be, upon the terms and conditions stated herein, u

3,769,231 Shares* VOLITIONRX LIMITED Common Stock UNDERWRITING AGREEMENT
Underwriting Agreement • March 18th, 2016 • Volitionrx LTD • In vitro & in vivo diagnostic substances • New York

VolitionRx Limited, a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of 3,769,231 shares of its Common Stock, par value $0.001 per share (the “Common Stock”). The aggregate of 3,769,231 shares to be purchased from the Company are called the “Firm Shares.” In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional 565,384 shares of Common Stock (the “Additional Shares”) to cover over-allotments by the Underwriters, if any. The Firm Shares and the Additional Shares are collectively referred to in this Agreement as the “Shares.” Raymond James & Associates, Inc. is acting as the representative of the several Underwriters and in such capacity is referred to in this Agreement as the “Representative.”

Shares* PLx Pharma Inc. Common Stock UNDERWRITING AGREEMENT
Underwriting Agreement • January 5th, 2016 • PLX Pharma Inc. • Pharmaceutical preparations • New York

PLx Pharma Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of [__________] shares of its Common Stock, par value $0.001 per share (the “Common Stock”). The aggregate of [_______] shares to be purchased from the Company are called the “Firm Shares.” In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional [________] shares of Common Stock (the “Additional Shares”) to cover over-allotments by the Underwriters, if any. The Firm Shares and the Additional Shares are collectively referred to in this Agreement as the “Shares.” Raymond James & Associates, Inc. (“RJ&A”) is acting as the representative of the several Underwriters and in such capacity is referred to in this Agreement as the “Representative.”

AutoNDA by SimpleDocs
1,967,214 Shares* CAROLINA FINANCIAL CORPORATION Common Stock UNDERWRITING AGREEMENT
Underwriting Agreement • December 14th, 2015 • Carolina Financial Corp • State commercial banks • Florida

Carolina Financial Corporation, a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of 1,967,214 shares of its Common Stock, par value $0.01 per share (the “Common Stock”). The aggregate of 1,967,214 shares to be purchased from the Company are called the “Firm Shares.” In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional 295,082 shares of Common Stock (the “Additional Shares”) to cover over-allotments by the Underwriters, if any. The Firm Shares and the Additional Shares are collectively referred to in this Agreement as the “Shares.” Raymond James & Associates, Inc. is acting as the representative of the several Underwriters and in such capacity is referred to in this Agreement as the “Representative.”

600,000 Shares FIRST GUARANTY BANCSHARES, INC. Common Stock UNDERWRITING AGREEMENT
Underwriting Agreement • November 12th, 2015 • First Guaranty Bancshares, Inc. • Savings institution, federally chartered • New York
3,500,000 Shares CELADON GROUP, INC. UNDERWRITING AGREEMENT Common Stock
Underwriting Agreement • May 29th, 2015 • Celadon Group Inc • Trucking (no local) • New York

Celadon Group, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to Raymond James & Associates, Inc. (the “Underwriter”) shares of the Company’s common stock, par value $0.033 per share (the “Common Stock”). The aggregate of 3,500,000 shares to be purchased from the Company are called the “Firm Shares.” In addition, the Company has agreed to sell to the Underwriter, upon the terms and conditions stated herein, up to an additional 525,000 shares of Common Stock (the “Additional Shares”) to cover over-allotments by the Underwriter, if any. The Firm Shares and the Additional Shares are collectively referred to in this Agreement as the “Shares.”

2,640,000 Shares COVENANT TRANSPORTATION GROUP, INC. Class A Common Stock UNDERWRITING AGREEMENT
Underwriting Agreement • November 25th, 2014 • Covenant Transportation Group Inc • Trucking (no local) • New York

Covenant Transportation Group, Inc., a Nevada corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 2,640,000 shares (the “Firm Shares”) of the Company’s Class A Common Stock, par value $0.01 per share (the “Common Stock”). In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional 396,000 shares of Common Stock. The additional 396,000 shares to be sold by the Company are referred to in this Underwriting Agreement (this “Agreement”) as the “Additional Shares.” The Firm Shares and the Additional Shares are collectively referred to in this Agreement as the “Shares.” Stephens Inc. and BB&T Capital Markets, a division of BB&T Securities, LLC, are acting as the representatives of the several Underwriters and in such capacity are referred to in this Agreement as the “Representat

10,000,000 Shares CARROLS RESTAURANT GROUP, INC. Common Stock UNDERWRITING AGREEMENT
Underwriting Agreement • April 30th, 2014 • Carrols Restaurant Group, Inc. • Retail-eating places • New York

Carrols Restaurant Group, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 10,000,000 shares of the Company’s common stock, par value $0.01 per share (the “Common Stock). The aggregate of 10,000,000 shares of Common Stock to be purchased from the Company are called the “Firm Shares.” In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional 1,500,000 shares of Common Stock to cover over-allotments by the Underwriters, if any. The additional 1,500,000 shares to be sold by the Company are referred to in this Agreement as the “Additional Shares.” The Firm Shares and the Additional Shares are collectively referred to in this Agreement as the “Shares.” Raymond James & Associates, Inc. and Stephens Inc. are acting as the representatives of the several Unde

] Shares Tennessee Commerce Bancorp, Inc. Common Stock FORM OF UNDERWRITING AGREEMENT
Underwriting Agreement • July 26th, 2010 • Tennessee Commerce Bancorp, Inc. • State commercial banks • New York
18,000,000 Shares First Busey Corporation Common Stock UNDERWRITING AGREEMENT
Underwriting Agreement • September 29th, 2009 • First Busey Corp /Nv/ • State commercial banks • New York
7,700,000 Shares* PINNACLE FINANCIAL PARTNERS, INC. Common Stock UNDERWRITING AGREEMENT
Underwriting Agreement • June 11th, 2009 • Pinnacle Financial Partners Inc • National commercial banks • New York

Pinnacle Financial Partners, Inc., a Tennessee corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of 7,700,000 shares of its common stock, par value $1.00 per share (the “Common Stock”). The aggregate of 7,700,000 shares to be purchased from the Company are called the “Firm Shares.” In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional 1,155,000 shares of Common Stock (the “Additional Shares”) to cover over-allotments by the Underwriters, if any. The Firm Shares and the Additional Shares are collectively referred to in this Agreement as the “Shares.” Raymond James & Associates, Inc. is acting as the representative of the several Underwriters and in such capacity is referred to in this Agreement as the “Representative.”

2,500,000 Shares* BANCSHARES OF FLORIDA, INC. Common Stock UNDERWRITING AGREEMENT
Underwriting Agreement • April 24th, 2006 • Bancshares of Florida Inc • National commercial banks • Florida

Bancshares of Florida, Inc., a Florida corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of 2,500,000 shares of its Common Stock, par value $0.01 per share (the “Common Stock”). The aggregate of 2,500,000 shares to be purchased from the Company are called the “Firm Shares.” In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional 375,000 shares of Common Stock (the “Additional Shares”) to cover over-allotments by the Underwriters, if any. The Firm Shares and the Additional Shares are collectively referred to in this Agreement as the “Shares.” Raymond James & Associates, Inc. is acting as the representative of the several Underwriters and in such capacity is referred to in this Agreement as the “Representative.”

1,500,000 Shares DAWSON GEOPHYSICAL COMPANY Common Stock FORM OF UNDERWRITING AGREEMENT
Underwriting Agreement • February 15th, 2005 • Dawson Geophysical Co • Oil & gas field exploration services • Florida

Raymond James & Associates, Inc. 880 Carillon Parkway St. Petersburg, Florida 33716 As Representative of the Underwriters listed on Schedule I hereto

1,500,000 Shares* MAIN STREET BANKS, INC. Common Stock UNDERWRITING AGREEMENT
Underwriting Agreement • December 9th, 2004 • Main Street Banks Inc /New/ • Commercial banks, nec • Florida

Main Street Banks, Inc., a Georgia corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of 1,500,000 shares of its Common Stock, no par value per share (the “Common Stock”). The aggregate of 1,500,000 shares of Common Stock to be purchased from the Company are called the “Firm Shares.” In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional 225,000 shares of Common Stock (the “Additional Shares”) to cover over-allotments by the Underwriters, if any. The Firm Shares and the Additional Shares are collectively referred to in this Agreement as the “Shares.” Raymond James & Associates, Inc. (“Raymond James”) and SunTrust Capital Markets, Inc. are acting as the representatives of the several Underwriters and in such capacity are referred to in this Agreement as the “Representa

4,800,000 SHARES ARGONAUT GROUP, INC. Common Stock UNDERWRITING AGREEMENT
Underwriting Agreement • October 31st, 2003 • Argonaut Group Inc • Fire, marine & casualty insurance • Texas

Argonaut Group, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of 4,800,000 shares of its common stock, par value $0.10 per share (the “Common Stock”). The aggregate of 4,800,000 shares to be purchased from the Company are called the “Firm Shares.” In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional 720,000 shares of Common Stock (the “Additional Shares”) to cover over-allotments by the Underwriters, if any. The Firm Shares and the Additional Shares are collectively referred to in this Agreement as the “Shares.” Raymond James & Associates, Inc. is acting as the representative of the several Underwriters and in such capacity is referred to in this Agreement as the “Representative.”

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!